超13亿美元!礼来再次加注RNA编辑疗法,解码MNC巨头的技术卡位与临床野心

药渡
20 May

来源:药渡撰文:Pharmadeep编辑:活力哈哈5月15日,韩国生物制药公司Rznomics宣布与礼来(Eli Lilly)达成一项全球研发合作及许可协议,共同开发基于RNA编辑技术的遗传性听力损失疗法。根据协议,礼来若行使全部合作选项,总交易额将超13亿美元,并附带销售分成。礼来作为全球制药巨头,近年通过多项高额合作加速布局RNA编辑领域,从遗传性听力损失到代谢性疾病,其战略版图日渐清晰。本文...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10